Status: Target Validation

CGEN-15052 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.

Initial testing of CGEN-15052 expression in human cancer tissue samples indicated that CGEN-15052 is expressed in the tumor micro-environment of multiple cancers, such as lung and breast cancer.

In a series of functional experiments, CGEN-15052 has demonstrated robust inhibition of both human and mouse T cell activation. Furthermore, as expected from an immune checkpoint target candidate, expression of CGEN-15052 on cancer cells in a syngeneic mouse animal model enhances tumor growth compared with control cancer cells. 

These results suggest that this Compugen-discovered protein has the potential to serve as a highly promising immunotherapeutic target for multiple cancer types.